Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for energy industry professionals · Saturday, April 5, 2025 · 800,446,787 Articles · 3+ Million Readers

VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm

April 05, 2025 --

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Valneva SE (“Valneva” or “the Company”) (NASDAQ: VALN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Valneva is the subject of a CDC notice posted on February 25, 2025. According to the government agency, the "CDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ [Valneva's chikungunya virus vaccine] among people 65 years of age and older." Based on this news, Valneva’s American Depositary Receipt ("ADR") price fell by more than 13.5% over the next several trading sessions.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Powered by EIN Presswire

Distribution channels:

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release